AN2 Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
AN2 Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to 2023.
  • AN2 Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$14M, a 22.9% increase year-over-year.
  • AN2 Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$67M, a 5.86% decline year-over-year.
  • AN2 Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$69.6M, a 64.8% decline from 2022.
  • AN2 Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.3M, a 95.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.